Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Antibe Therapeutics (ATBPF)

Antibe Therapeutics (ATBPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Antibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan...

ATE.VN : 0.340 (-2.86%)
ATBPF : 0.2569 (-3.46%)
MHMNF : 54.5000 (unch)
Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences:

ATE.VN : 0.340 (-2.86%)
ATBPF : 0.2569 (-3.46%)
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company's unaudited...

ATE.VN : 0.340 (-2.86%)
ATBPF : 0.2569 (-3.46%)
Antibe Therapeutics Announces Results of Annual and Special Meeting

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular...

ATE.VN : 0.340 (-2.86%)
ATBPF : 0.2569 (-3.46%)
Antibe Therapeutics Engages Stern IR for Investor Relations Services

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. ("Stern IR") to expand the Company's investor relations program and support efforts...

ATE.VN : 0.340 (-2.86%)
ATBPF : 0.2569 (-3.46%)
Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Inc.:

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
IIROC Trading Resumption - ATE

Trading resumes in:

ATBPF : 0.2569 (-3.46%)
Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346....

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Announces the Hiring of Chief Medical Officer

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief Medical Officer ("CMO"). An anesthesiologist, Dr. Stauffer has served...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The Company's...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging,...

ATBPF : 0.2569 (-3.46%)
ATE.VN : 0.340 (-2.86%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar